# Vaccination Schedule under Conditions of Limited Vaccine Production Rate

^{*}

## Abstract

**:**

## 1. Introduction and Background

- the problem of distributing protective actions (PDPA)–(pessimistic), which assumes high availability of vaccines and a constant probability of disease in each social and occupational group that does not decrease even if the number of vaccinated people increases;
- the problem of distributing protective actions with a herd immunity threshold(PDPAHIT)–(optimistic) which assumes high availability of vaccines and a variable probability of disease in each social and occupational group that changes as the threshold of herd immunity is reached.

#### Positioning of the Paper

## 2. Materials and Methods

- Direct level—lowering the probability of severe disease for a vaccinated individual. All vaccinated individuals reduce the overall probability of fatal cases in the region.
- Indirect level—lowering the probability of infection for vaccinated individuals. The vaccine minimizes the probability of infection so that a growing group of vaccinated individuals lowers the probability of infection.

- ${P}_{{S}_{zg}}$— the probability of severe course of the disease,
- ${P}_{{S}_{zk}}$— the probability of infection in the vaccinated individual,
- ${S}_{zg}$—the effectiveness of the vaccine against the severe course of the disease,
- ${S}_{zk}$—the effectiveness of the vaccine against the infection,
- ${P}_{zg}$—the probability of death of a given individual, e.g., depending on the age,
- ${P}_{zk}$—the probability of an infection in a given area during an active vaccination program,
- Z—the percentage of vaccinated individuals expressed as a fraction of the total population,
- ${P}_{z}$—the probability of infection in a given area, e.g., depending on the level of urbanization.

#### 2.1. The Problem of Distributing Protective Actions on the Example of Vaccination

#### 2.2. The Problem of Distributing Protective Actions with a Herd Immunity Threshold

## 3. Results

**Social groups**—the first issue is to identify social groups in a given territory with a constant probability of infection. In the presented example, the territorial division of the country was used, and the probability of infection was related to the population density, which is presented in Table 4.

**Available vaccines**—these are characterized only by the probability of preventing infection. This data for individual vaccines are presented in Table 5.

**Vaccine delivery schedule**—the planned delivery schedule for each vaccine type is shown in Table 6.

- “District 1” has a medium-sized population (2,901,225 residents) and one of the lowest probabilities of infection (0.01);
- “District 10” has a relatively small population (1,181,533.00 inhabitants) and one of the highest probabilities of infection (0.09).

- “District 1”—329,623 people
- “District 10”—232,946 people

## 4. Discussion

## 5. Conclusions

## Author Contributions

## Funding

## Institutional Review Board Statement

## Informed Consent Statement

## Data Availability Statement

## Conflicts of Interest

## Abbreviations

DMU | Decision Making Unit |

DSS | Decision Support System |

MIP | Mix-Integer Programming |

NPI | Non-Pharmaceutical Interventions |

PDPA | Problem of Distributing Protective Actions |

PDPAHIT | Problem of Distributing Protective Actions with a Herd Immunity Threshold |

## References

- Gupta, R.; Morain, S.R. Ethical allocation of future COVID-19 vaccines. J. Med. Ethics
**2021**, 47, 137–141. [Google Scholar] [CrossRef] - Hughes, K.; Gogineni, V.; Lewis, C.; Deshpande, A. Considerations for fair prioritization of COVID-19 vaccine and its mandate among healthcare personnel. Curr. Med. Res. Opin.
**2021**, 37, 907–909. [Google Scholar] [CrossRef] [PubMed] - Russell, F.M.; Greenwood, B. Who should be prioritised for COVID-19 vaccination? Hum. Vaccines Immunother.
**2021**, 17, 1317–1321. [Google Scholar] [CrossRef] - Bolcato, M.; Rodriguez, D.; Feola, A.; Mizio, G.D.; Bonsignore, A.; Ciliberti, R.; Tettamanti, C.; Aurilio, M.T.; Aprile, A. COVID-19 Pandemic and Equal Access to Vaccines. Vaccines
**2021**, 9, 538. [Google Scholar] [CrossRef] - Yang, J.; Zheng, W.; Shi, H.; Yan, X.; Dong, K.; You, Q.; Zhong, G.; Gong, H.; Chen, Z.; Jit, M.; et al. Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Med.
**2021**, 19, 45. [Google Scholar] [CrossRef] - Piraveenan, M.; Sawleshwarkar, S.; Walsh, M.; Zablotska, I.; Bhattacharyya, S.; Farooqui, H.H.; Bhatnagar, T.; Karan, A.; Murhekar, M.; Zodpey, S.; et al. Optimal governance and implementation of vaccination programmes to contain the COVID-19 pandemic. R. Soc. Open Sci.
**2021**, 8, 210429. [Google Scholar] [CrossRef] - Savoia, E.; Piltch-Loeb, R.; Goldberg, B.; Miller-Idriss, C.; Hughes, B.; Montrond, A.; Kayyem, J.; Testa, M.A. Predictors of COVID-19 Vaccine Hesitancy: Socio-Demographics, Co-Morbidity, and Past Experience of Racial Discrimination. Vaccines
**2021**, 9, 767. [Google Scholar] [CrossRef] [PubMed] - Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of covid-19 vaccination during the covid-19 pandemic in china. Vaccines
**2020**, 8, 482. [Google Scholar] [CrossRef] - Sattar, N.S.; Arifuzzaman, S. COVID-19 Vaccination Awareness and Aftermath: Public Sentiment Analysis on Twitter Data and Vaccinated Population Prediction in the USA. Appl. Sci.
**2021**, 11, 6128. [Google Scholar] [CrossRef] - Centers for Desease Control and Prevention. Different COVID-19 Vaccines; U.S. Department of Health and Human Services: Washington, DC, USA, 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html (accessed on 10 December 2021).
- European Medcines Agency. Human Medicine European Public Assessment Report (EPAR): COVID-19 Vaccine Janssen (Updated). Technical Report. 2021. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen (accessed on 10 December 2021).
- European Medicines Agency. Human Medicine European Public Assessment Report (EPAR): Comirnaty (Updated). Technical Report, Brussels. 2021. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty (accessed on 10 December 2021).
- European Medicines Agency. Human Medicine European Public Assessment Report (EPAR): Spikevax (Previously COVID-19 Vaccine Moderna) (Updated). Technical Report, Brussels. 2021. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca (accessed on 10 December 2021).
- European Medicines Agency. Human Medicine European Public Assessment Report (EPAR): Vaxzevria (Previously COVID-19 Vaccine AstraZeneca) (Updated). Technical Report, Brussels. 2021. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax (accessed on 10 December 2021).
- Lv, H.; Wu, N.C.; Mok, C.K. COVID-19 vaccines: Knowing the unknown. Eur. J. Immunol.
**2020**, 50, 939–943. [Google Scholar] [CrossRef] - Ke, R.; Romero-Severson, E.; Sanche, S.; Hengartner, N. Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. J. Theor. Biol.
**2021**, 517, 110621. [Google Scholar] [CrossRef] [PubMed] - Ricco, M.; De Nard, F.; Peruzzi, S. Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2? Infect. Dis. Now
**2021**, 51, 402–405. [Google Scholar] [CrossRef] - Alleman, T.; Torfs, E.; Nopens, I. Covid-19: From Model Prediction to Model Predictive. 2020. Available online: https://biomath.ugent.be/sites/default/files/2020-04/Alleman_etal_v2.pdf (accessed on 10 December 2021).
- Ko, S.C.; Cheng, K.C.; Chuang, Y.C. Herd immunity, vaccine development and BCG effects in COVID-19. J. Intern. Med. Taiwan
**2020**, 31, 254–261. [Google Scholar] [CrossRef] - World Health Organization. Prioritized Infectious Disease and Economic Modeling Questions; Technical Report; World Health Organization: Geneva, Switzerland, 2020. [Google Scholar]
- Toner, E.; Barnill, A.; Krubiner, C.; Bernstein, J.; Watson, M.; Martin, E.; Potter, C.; Hosangadi, D.; Connell, N.; Watson, C.; et al. Interim Framework for COVID-19 Vaccine Allocation and Distribution in the United States; Technical Report; The Johns Hopkins Center for Health Security: Baltimore, MD, USA, 2020; Available online: https://www.centerforhealthsecurity.org/our-work/publications/interim-framework-for-covid-19-vaccine-allocation-and-distribution-in-the-us (accessed on 10 December 2021).
- So, A.D.; Woo, J. Reserving coronavirus disease 2019 vaccines for global access: Cross sectional analysis. BMJ
**2020**, 371, m4750. [Google Scholar] [CrossRef] - Siedner, M.J.; Alba, C.; Fitzmaurice, K.P.; Gilbert, R.F.; Scott, J.A.; Shebl, F.M.; Ciaranello, A.; Reddy, K.P.; Freedberg, K.A. Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries. medRxiv
**2021**. [Google Scholar] [CrossRef] - Acuña-Zegarra, M.A.; Díaz-Infante, S.; Baca-Carrasco, D.; Olmos-Liceaga, D. COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses. Math. Biosci.
**2021**, 337, 108614. [Google Scholar] [CrossRef] - Makhoul, M.; Ayoub, H.H.; Chemaitelly, H.; Seedat, S.; Mumtaz, G.R.; Al-Omari, S.; Abu-Raddad, L.J. Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. Vaccines
**2020**, 8, 668. [Google Scholar] [CrossRef] - Gumel, A.B.; Iboi, E.A.; Ngonghala, C.N.; Elbasha, E.H. A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations. Infect. Dis. Model.
**2021**, 6, 148–168. [Google Scholar] [CrossRef] - Fuady, A.; Nuraini, N.; Sukandar, K.K.; Lestari, B.W. Targeted vaccine allocation could increase the covid-19 vaccine benefits amidst its lack of availability: A mathematical modeling study in indonesia. Vaccines
**2021**, 9, 462. [Google Scholar] [CrossRef] - Amaku, M.; Covas, D.T.; Coutinho, F.A.B.; Azevedo, R.S.; Massad, E. Modelling the impact of delaying vaccination against SARS-CoV-2 assuming unlimited vaccine supply. Theor. Biol. Med. Model.
**2021**, 18, 14. [Google Scholar] [CrossRef] - Iboi, E.A.; Ngonghala, C.N.; Gumel, A.B. Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.? Infect. Dis. Model.
**2020**, 5, 510–524. [Google Scholar] [CrossRef] - Gumel, A.B.; Iboi, E.A.; Ngonghala, C.N.; Ngwa, G.A. Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S. Front. Public Health
**2021**, 9, 2020-12. [Google Scholar] [CrossRef] - Bubar, K.M.; Reinholt, K.; Kissler, S.M.; Lipsitch, M.; Cobey, S.; Grad, Y.H.; Larremore, D.B. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science
**2021**, 371, 916–921. [Google Scholar] [CrossRef] - Campos, E.L.; Cysne, R.P.; Madureira, A.L.; Mendes, G.L. Multi-generational SIR modeling: Determination of parameters, epidemiological forecasting and age-dependent vaccination policies. Infect. Dis. Model.
**2021**, 6, 751–765. [Google Scholar] [CrossRef] - Foy, B.H.; Wahl, B.; Mehta, K.; Shet, A.; Menon, G.I.; Britto, C. Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. Int. J. Infect. Dis.
**2021**, 103, 431–438. [Google Scholar] [CrossRef] - Zhao, S.; Chen, H. Modeling the epidemic dynamics and control of COVID-19 outbreak in China. Quant. Biol.
**2020**, 8, 1–9. [Google Scholar] [CrossRef] [Green Version] - Ala’raj, M.; Majdalawieh, M.; Nizamuddin, N. Modeling and forecasting of COVID-19 using a hybrid dynamic model based on SEIRD with ARIMA corrections. Infect. Dis. Model.
**2021**, 6, 98–111. [Google Scholar] [CrossRef] - Cooper, I.; Mondal, A.; Antonopoulos, C.G. A SIR model assumption for the spread of COVID-19 in different communities. Chaos Solitons Fractals
**2020**, 139, 110057. [Google Scholar] [CrossRef] - Wu, J.T.; Leung, K.; Leung, G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet
**2020**, 395, 689–697. [Google Scholar] [CrossRef] [Green Version] - Kucharski, A.J.; Russell, T.W.; Diamond, C.; Liu, Y.; Edmunds, J.; Funk, S.; Eggo, R.M.; Sun, F.; Jit, M.; Munday, J.D.; et al. Early dynamics of transmission and control of COVID-19: A mathematical modelling study. Lancet Infect. Dis.
**2020**, 20, 553–558. [Google Scholar] [CrossRef] [Green Version] - Wrigley-Field, E.; Kiang, M.V.; Riley, A.R.; Barbieri, M.; Chen, Y.H.; Duchowny, K.A.; Matthay, E.C.; Riper, D.V.; Jegathesan, K.; Bibbins-Domingo, K.; et al. Geographically-targeted COVID-19 vaccination is more equitable than age-based thresholds alone. Sci. Adv.
**2021**, 20, eabj2099. [Google Scholar] [CrossRef] - Chen, X.; Li, M.; Simchi-Levi, D.; Zhao, T. Allocation of COVID-19 Vaccines Under Limited Supply. SSRN Electron. J.
**2020**. [Google Scholar] [CrossRef] - Lemke, M.K. Commercial truck drivers should be a priority population for COVID-19 vaccinations. Am. J. Ind. Med.
**2021**, 64, 217–219. [Google Scholar] [CrossRef] - Yu, H.; Han, S.; Cai, J.; Yang, J.; Zhang, J.; Wu, Q.; Zheng, W.; Shi, H.; Ajelli, M.; Zhou, X. Dynamic optimization of COVID-19 vaccine prioritization in the context of limited supply. Res. Sq. Nat. Portf. 2021. [CrossRef]
- MacIntyre, C.R.; Costantino, V.; Trent, M. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine
**2021**, in press. [Google Scholar] [CrossRef] - Shim, E. Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea. J. Clin. Med.
**2021**, 10, 591. [Google Scholar] [CrossRef] - Allam, M.F.; Andraous, F.; Amin, G.E.E.D. Vaccination Schedules and COVID-19 Risk. Open Microbiol. J.
**2020**, 14, 278–280. [Google Scholar] [CrossRef] - Li, Q.; Norman, S.; Guthrie, P.; Gachoya, J.; Sebakijje, J.; Leftridge, Z.; Willis, C.G.; Kishore, A.; Breakenridge, M.; Spence, C. Strategies used to meet the challenges of mass COVID-19 vaccination by the pharmacy department in a large academic medical center. Am. J. Health-Syst. Pharm.
**2021**, 78, 1724–1731. [Google Scholar] [CrossRef] - Hanly, M.; Churches, T.; Fitzgerald, O.; Caterson, I.; MacIntyre, C.R.; Jorm, L. Modelling vaccination capacity at mass vaccination hubs and general practice clinics. medRxiv
**2021**. [Google Scholar] [CrossRef] - More attacks on Covid-19 vaccine suppliers and supply chain. Comput. Fraud. Secur.
**2020**, 2020, 1–3. [CrossRef] - Pagliusi, S.; Jarrett, S.; Hayman, B.; Kreysa, U.; Prasad, S.D.; Reers, M.; Hong Thai, P.; Wu, K.; Zhang, Y.T.; Baek, Y.O.; et al. Emerging manufacturers engagements in the COVID-19 vaccine research, development and supply. Vaccine
**2020**, 38, 5418–5423. [Google Scholar] [CrossRef] - Antal, C.; Cioara, T.; Antal, M.; Anghel, I. Blockchain Platform For COVID-19 Vaccine Supply Management. IEEE Open J. Comput. Soc.
**2021**, 2, 164–178. [Google Scholar] [CrossRef] - Dai, D.; Wu, X.; Si, F. Complexity analysis of cold chain transportation in a vaccine supply chain considering activity inspection and time-delay. Adv. Differ. Equ.
**2021**, 2021, 39. [Google Scholar] [CrossRef] [PubMed] - Jarrett, S.; Wilmansyah, T.; Bramanti, Y.; Alitamsar, H.; Alamsyah, D.; Krishnamurthy, K.R.; Yang, L.; Pagliusi, S. The role of manufacturers in the implementation of global traceability standards in the supply chain to combat vaccine counterfeiting and enhance safety monitoring. Vaccine
**2020**, 38, 8318–8325. [Google Scholar] [CrossRef] [PubMed] - Golan, M.S.; Trump, B.D.; Cegan, J.C.; Linkov, I. The Vaccine Supply Chain: A Call for Resilience Analytics to Support COVID-19 Vaccine Production and Distribution. In COVID-19: Systemic Risk and Resilience; Springer: Cham, Switzerland, 2021; pp. 389–437. [Google Scholar] [CrossRef]
- Burton, D.R.; Topol, E.J. Variant-proof vaccines—Invest now for the next pandemic. Nature
**2021**, 590, 386–388. [Google Scholar] [CrossRef] - Hu, H.; Nigmatulina, K.; Eckhoff, P. The scaling of contact rates with population density for the infectious disease models. Math. Biosci.
**2013**, 244, 125–134. [Google Scholar] [CrossRef] [PubMed] - Bhadra, A.; Mukherjee, A.; Sarkar, K. Impact of population density on Covid-19 infected and mortality rate in India. Model. Earth Syst. Environ.
**2021**, 7, 623–629. [Google Scholar] [CrossRef] - Moghadas, S.M.; Vilches, T.N.; Zhang, K.; Nourbakhsh, S.; Sah, P.; Fitzpatrick, M.C.; Galvani, A.P. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol.
**2021**, 19, e3001211. [Google Scholar] [CrossRef] [PubMed] - Vilches, T.N.; Zhang, K.; Van Exan, R.; Langley, J.M.; Moghadas, S.M. Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine
**2021**, 39, 2360–2365. [Google Scholar] [CrossRef] - Wolsey, L.A. Integer programming duality: Price functions and sensitivity analysis. Math. Program.
**1981**, 20, 173–195. [Google Scholar] [CrossRef] - Schrage, L.; Wolsey, L. Sensitivity analysis for branch and bound integer programming. Oper. Res.
**1985**, 33, 1008–1023. [Google Scholar] [CrossRef] - Roos, C. Linear Optimization. In Encyclopedia of Physical Science and Technology; Elsevier: Amsterdam, The Netherlands, 2003; pp. 597–616. [Google Scholar] [CrossRef]
- Higgins, S.T.; Klemperer, E.M.; Coleman, S.R. Looking to the empirical literature on the potential for financial incentives to enhance adherence with COVID-19 vaccination. Prev. Med.
**2021**, 145, 106421. [Google Scholar] [CrossRef] [PubMed]

**Table 1.**The main factors underlying severe COVID-19 infection [10].

Age Range [Years] | Cases | Hospitalization | Death |
---|---|---|---|

0–4 | <1x | 2x | 2x |

5–17 | Reference group | Reference group | Reference group |

18–29 | 2x | 6x | 10x |

30–39 | 2x | 10x | 45x |

40–49 | 2x | 15x | 130x |

50–64 | 2x | 25x | 440x |

65–74 | 1x | 40x | 1300x |

75–84 | 1x | 65x | 3200x |

85+ | 2x | 95x | 8700x |

Characteristics | Vaccines | |||
---|---|---|---|---|

Pfizer | Moderna | AstraZeneca | JohnsonAndJohnson | |

Number of doses | 2 | 2 | 2 | 1 |

Vaccine efficacy against COVID-19 | 0.950 | 0.941 | 0.595 | 0.669 |

Vaccine efficacy against severe COVID-19 | no data | 1 | 1 | 0.854 |

Sets | ||

$\mathcal{T}$ | = | the set of identical consecutive planning periods; |

$\mathcal{V}$ | = | the set of available protective measures (e.g., different preparations) to prevent an adverse phenomenon (e.g., death, disease); |

$\mathcal{R}$ | = | the set of homogeneous social groups defined based on a selected criterion (e.g., age, occupation, place of residence); |

Parameters | ||

M | – | a sufficiently large constant; |

${d}_{r}$ | – | the size of the group r; |

${p}_{r}^{R}$ | – | the probability of occurrence of an adverse phenomenon in a person in a given group r not covered by protective measures; |

${p}_{v}^{V}$ | – | the probability of occurrence of an adverse phenomenon in an individual covered by protective action v; |

${b}_{vt}$ | – | maximum available number of units of protective action v in period t; |

${C}_{t}$ | – | maximum available number of units of all protective actions in period t; |

f | – | the percentage of applied protective actions ensuring collective immunity of the community to the adverse phenomenon; |

Decision Variables | ||

${x}_{rvt}$ | – | the number of individuals subjected to the protective action v in group r in period t; |

${I}_{rt}$ | – | the expected value of the number of individuals in group r subject to the adverse phenomenon in period t; |

${y}_{rt}$ | = | 1 if group r achieved herd protection in period t, else 0 |

Name | Population Size | pR |
---|---|---|

District 1 | 2,901,225 | 0.01 |

District 2 | 2,077,775 | 0.06 |

District 3 | 2,117,619 | 0.05 |

District 4 | 1,014,548 | 0.08 |

District 5 | 2,466,322 | 0.03 |

District 6 | 3,400,577 | 0.03 |

District 7 | 5,403,412 | 0.07 |

District 8 | 986,506 | 0.04 |

District 9 | 2,129,015 | 0.09 |

District 10 | 1,181,533 | 0.09 |

District 11 | 2,333,523 | 0.07 |

District 12 | 4,533,565 | 0.04 |

District 13 | 1,241,546 | 0.06 |

District 14 | 1,428,983 | 0.09 |

District 15 | 3,493,969 | 0.06 |

District 16 | 1,701,030 | 0.09 |

Name | pR |
---|---|

Vaccine 1 | 0.950 |

Vaccine 2 | 0.941 |

Vaccine 3 | 0.595 |

Vaccine 4 | 0.669 |

Period | Vaccine 1 | Vaccine 2 | Vaccine 3 | Vaccine 4 |
---|---|---|---|---|

0 | 873,000 | 0 | 172,000 | 0 |

1 | 873,000 | 204,000 | 161,000 | 0 |

2 | 873,000 | 0 | 268,000 | 300,000 |

3 | 873,000 | 287,000 | 765,000 | 0 |

4 | 873,000 | 0 | 172,000 | 0 |

5 | 873,000 | 204,000 | 161,000 | 0 |

6 | 873,000 | 0 | 268,000 | 300,000 |

7 | 873,000 | 287,000 | 765,000 | 0 |

8 | 873,000 | 0 | 172,000 | 0 |

9 | 873,000 | 204,000 | 161,000 | 0 |

10 | 873,000 | 0 | 268,000 | 300,000 |

11 | 873,000 | 287,000 | 765,000 | 0 |

Period | Vaccine 1 | Vaccine 2 | Vaccine 3 | Vaccine 4 |
---|---|---|---|---|

0 | 172,000 | 0 | 0 | 0 |

1 | 0 | 0 | 204,000 | 0 |

2 | 0 | 0 | 0 | 0 |

3 | 92,911 | 0 | 0 | 630,527 |

4 | 0 | 0 | 0 | 0 |

5 | 0 | 0 | 0 | 0 |

6 | 0 | 0 | 0 | 0 |

7 | 0 | 0 | 0 | 0 |

8 | 0 | 0 | 0 | 0 |

9 | 0 | 0 | 0 | 0 |

10 | 0 | 0 | 0 | 0 |

11 | 0 | 0 | 0 | 0 |

Period | Vaccine 1 | Vaccine 2 | Vaccine 3 | Vaccine 4 |
---|---|---|---|---|

0 | 172,000 | 0 | 0 | 714,150 |

1 | 0 | 0 | 0 | 0 |

2 | 0 | 0 | 0 | 0 |

3 | 0 | 0 | 0 | 0 |

4 | 0 | 0 | 0 | 0 |

5 | 0 | 0 | 0 | 0 |

6 | 0 | 0 | 0 | 0 |

7 | 0 | 0 | 0 | 0 |

8 | 0 | 0 | 0 | 0 |

9 | 0 | 0 | 0 | 0 |

10 | 0 | 0 | 0 | 0 |

11 | 0 | 0 | 0 | 0 |

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

## Share and Cite

**MDPI and ACS Style**

Książek, R.; Kapłan, R.; Gdowska, K.; Łebkowski, P.
Vaccination Schedule under Conditions of Limited Vaccine Production Rate. *Vaccines* **2022**, *10*, 116.
https://doi.org/10.3390/vaccines10010116

**AMA Style**

Książek R, Kapłan R, Gdowska K, Łebkowski P.
Vaccination Schedule under Conditions of Limited Vaccine Production Rate. *Vaccines*. 2022; 10(1):116.
https://doi.org/10.3390/vaccines10010116

**Chicago/Turabian Style**

Książek, Roger, Radosław Kapłan, Katarzyna Gdowska, and Piotr Łebkowski.
2022. "Vaccination Schedule under Conditions of Limited Vaccine Production Rate" *Vaccines* 10, no. 1: 116.
https://doi.org/10.3390/vaccines10010116